Press Releases

- In the pivotal trial, more than twice as many children achieved clear or almost clear skin and more than four times achieved itch reduction with Dupixent plus topical corticosteroids (TCS) compared to TCS alone

Sutimlimab targets C1-activated hemolysis in cold agglutinin disease (CAD)

- Emerging data demonstrate commitment to advancing cancer care, including two fully in-house investigational compounds: a potential best-in-class oral SERD for breast cancer and a first-in-class anti-CEACAM5 antibody-drug conjugate for non-small cell lung cancer

- IKEMA trial results released early based on recommendation of an Independent Data Monitoring Committee

Objective responses seen in 29% of patients with locally advanced basal cell carcinoma (BCC)